Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Radiation dose-response of human tumors1995 · 334 citations
2. 2R: A Language and Environment for Statistical Computing2000 · 353,004 citations
3. 3Yttrium-90 DOTATOC: first clinical results1999 · 328 citations
4. 4Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management2020 · 43 citations
5. 5Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry2017 · 206 citations